newsfilter
← Latest News
GlobeNewswire·

Adhera Therapeutics Signs Letter of Intent to Acquire CD71-Targeted Cancer Therapy Paclitaxel Gallium Transferrin

Baton Rouge, LA, July 19, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB:ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, today announces that the Company has entered a Heads of Terms (also known as a Letter of